Vol. 22/No. 16 | OncologyLive

Chemotherapy-Free Strategies Chart a New Course for Ph-Positive ALL

August 24, 2021


A new era for patients with newly diagnosed Philadelphia chromosomepositive acute lymphoblastic leukemia may be on the horizon as investigative efforts aimed away from chemotherapy-based regimens prove efficacious.

Future of Care for PCNSL Relies on Adapting Personalized Approaches

August 23, 2021


Primary central nervous system lymphoma is a rare and aggressive variant of extranodal non-Hodgkin lymphoma that occurs in the brain, spinal cord, cerebrospinal fluid, or eyes in the absence of systemic disease.

ASCO Roadmap Provides Path Forward for Clinician Well-Being

August 20, 2021

A collaborative initiative between the American Society of Clinical Oncology and the American Medical Association has the goal of improving well-being and reducing burnout by leveraging a quality improvement framework and model.

Novel Compound Looks to Shake Up mCRPC Treatment Landscape

August 19, 2021

The discovery of an agent with a unique mechanism of action led investigators to examine sabizabulin, an oral therapy that binds to the colchicine binding site on the microtubule to crosslink α and β tubulin and inhibits microtubule polymerization.

3 Precision Era Biomarkers Get a Closer Look

August 18, 2021

Cover Story

Circulating tumor DNA, tumor mutational burden, and homologous recombination deficiency are 3 emerging biomarkers for tailoring therapy need further clinical and technical clarity to support robust use in daily practice.

Tagawa Takes Stock of Future of Sacituzumab Govitecan in Urothelial Carcinoma

August 16, 2021


Sacituzumab govitecan-hziy, a Trop-2directed antibody-drug conjugate with an SN-38 payload, has carved out a role in the treatment landscape for patients with locally advanced or metastatic urothelial cancer following accelerated approval by the FDA.

Misinformation on Cancer Prevention Stems from COVID-19 Communication Efforts

August 15, 2021

One year ago, few objective observers would have suggested that the percentage of individuals who are currently fully vaccinated is less than 30%, despite the well-documented real-world success data for the vaccines in preventing serious illness, hospitalizations, and death from COVID-19 infection.